PCSK9 inhibitors: Going forward and beyond

被引：1
作者：
Attar, Armin [1 ]
机构：
[1] Shiraz Univ Med Sci, Dept Cardiovasc Med, TAHA Clin Trial Grp, Shiraz, Iran
来源：
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY | 2021年 / 28卷 / 08期
关键词：
LDL-CHOLESTEROL; SECONDARY ANALYSIS; CLINICAL-EFFICACY; EVOLOCUMAB; SAFETY; STATIN;
D O I：
10.1177/2047487320916964
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：803 / 804
页数：2
相关论文
共 50 条
  • [31] PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
    Zulkapli, Rahayu
    Abd Muid, Suhaila
    Wang, Seok Mui
    Nawawi, Hapizah
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (06)
  • [32] Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias
    Rached, Fabiana
    Santos, Raul D.
    CURRENT CARDIOLOGY REPORTS, 2021, 23 (07)
  • [33] Plasma kinetics of mature PCSK9, furin-cleaved PCSK9, and Lp(a) with or without administration of PCSK9 inhibitors in acute myocardial infarction
    Nakamura, Akihiro
    Kanazawa, Masanori
    Kagaya, Yuta
    Kondo, Masateru
    Sato, Kenjiro
    Endo, Hideaki
    Nozaki, Eiji
    JOURNAL OF CARDIOLOGY, 2020, 76 (04) : 395 - 401
  • [34] Role of PCSK9 inhibitors in the management of dyslipidaemia
    Nair, Tiny
    INDIAN HEART JOURNAL, 2024, 76 : S44 - S50
  • [35] Will the PCSK9 Inhibitors Be Employers' "Line in the Sand"?
    Mehr, Stanton R.
    AMERICAN HEALTH AND DRUG BENEFITS, 2016, 9 (03) : 171 - 174
  • [36] PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives
    Nicholls, Stephen J.
    KARDIOLOGIA POLSKA, 2023, 81 (02) : 115 - 122
  • [37] PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
    Do, Rose Q.
    Vogel, Robert A.
    Schwartz, Gregory G.
    CURRENT CARDIOLOGY REPORTS, 2013, 15 (03)
  • [38] PCSK9 Inhibitors: A Technology Worth Paying For?
    Weintraub, William S.
    Gidding, Samuel S.
    PHARMACOECONOMICS, 2016, 34 (03) : 217 - 220
  • [39] PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
    Rose Q. Do
    Robert A. Vogel
    Gregory G. Schwartz
    Current Cardiology Reports, 2013, 15
  • [40] PCSK9 inhibitors in the prevention of cardiovascular disease
    James Latimer
    Jonathan A. Batty
    R. Dermot G. Neely
    Vijay Kunadian
    Journal of Thrombosis and Thrombolysis, 2016, 42 : 405 - 419
12345